the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Backup Compound Strategies: Best Practices for Reducing Phase II Risk

Published by Insight Pharma Reports Contact us : +1-860-674-8796
Published 2007/09 Content info 134 pages
Product code CD56333
Price From  US $ 2995 Order/Price list
US $ 2995 Hard Copy
US $ 3750 PDF by E-mail (Single Site License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Abstract

Backup compound planning has risen in importance as the percentage of R&D projects focused on unprecedented targets has skyrocketed. Heads of R&D and chemistry, therapeutic area heads, portfolio analysts, and project managers all recognize that there is no surer way to minimize Phase II risk than a well thought-out backup plan.

This report drives home real world experiences and best practices in backup compound strategies with:

  • Case studies of actual backup programs at large and small pharma companies
  • Expert interviews with senior R&D managers who discuss the nuts and bolts of backup planning, and offer best practices and cautionary examples
  • A proprietary survey of the views, practices, and plans of individuals in R&D involved with backup decision making.

Backup Compound Strategies: Best Practices for Reducing Phase II Risk details the strategic and tactical aspects of backup planning, examining organizational issues and business considerations such as:

  • What organizational design - pure functional vs pure project, with varying matrix forms in between - is best suited to backup planning
  • What to do with backups once the prototype has entered the market
  • Determining the level of resources available to a backup program

Despite the paramount importance of having well-thought-out SOPs for backup compounds, CHI' s proprietary research shows that nearly 40% of companies surveyed (N=36) do not have a clearly articulated way of thinking about backup compounds, and an additional 14% employs a backup plan only at "some sites." This is not surprising in view of the daunting number of factors to be taken into account in the backup calculation. Such key decisions as the number of backups, when to begin development, and the level of investment required are, in turn, determined by numerous strategic and tactical factors, such as:

  • The type of company
  • The importance of the therapeutic area to the company
  • The importance of the project to the therapeutic area
  • The risk of the prototype molecule' s attrition for chemical or biological reasons
  • Whether the project strongly meets the target product profile criteria Etc.

The most complete backup strategies include one or more backup programs in addition to the backup or follow-on compounds for the primary compound. These additional backup programs may be based on the same target in the same biological pathway, or on a target in a different biological pathway.

This report is a trove of proven experience and sophisticated thinking about a critical but often neglected R&D decision.

Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.